ARROS-1 Trial

[Slide 1] 2023 Conference #WCLC25 ARROS-1: Objective Response in ROS1 TKI Pre-treated Patients Advanced ROS1+ Any prior ROS1 TKI 1 prior ROS1 TKI Responses were also observed in NSCLC (range 1-4) (crizotinib or entrectinib) patients previously treated with: RECIST 1.1 by BICR 1 chemotherapy 1 chemotherapy 22 prior ROS1 TKIs * chemotherapy: ORR, % (n/N) 44% (51/117) 51% (28/55) ORR = 38% (22/58; 95% Cl: [26, 52]) (95% CI] [34, 53] [37,65] Prior repotrectinib: ORR . 47% (8/17), DOR range 3.5 to 17.2 months CR, % (n/N) 1% (1/117) 2% (1/55) Prior taletrectinib: ORR . 43% (3/7), Prior crizotinib only 1 chemotherapy ORR - 68% (19/28) Prior entrectinib only 1 chemotherapy ORR - 33% (9/27). DOR range 5.2 to 7.0+ months so 1 Prior ROS1 TKI (crizotinib or entrectinib) = chemotherapy 40 20 * change Insure a 1 Prior crizotinib 0 30 Prior entrectinib 40 60 + Prior chemotherapy 80 100 (ata off March 21,2025 CI. confidence intervat OR complete response PD, progresse disease, PR partial response, RECIST 1.1. Response Evaluation Citteria n Sold tumours version 1.1.SD stable disease

[Slide 1] ------ ARROS-1: Summary PIVOTAL DATASET Preliminary In the pivotal dataset for TKI pre-treated patients with Any prior 1 prior ROS1 TKI Advanced advanced ROS1+ NSCLC, zidesamtinib demonstrated a ROS1 TKIs (crizotinib or ROS1 ROS1+ NSCLC (range 1-4) entrectinib) TKI-naive clinical profile consistent with its preclinical design goals: 1 chemotherapy 1 chemotherapy Durable activity, including in heavily pre-treated patients that ORR (BICR) 44% 51% 89% have exhausted available options (including prior % DOR repotrectinib or taletrectinib) and patients with the ROS1 78% 93% 96% : 12 months G2032R resistance mutation % DOR 62% 93% : 18 months Durable intracranial responses, including in patients who % PFS 48% 68% previously received the brain-penetrant TKIs entrectinib, 11 12 months lorlatinib, repotrectinib or taletrectinib % PFS 40% 68% E 18 months Generally well-tolerated with low rates of dose reduction Any prior Prior crizotinib Intracranial ROS1 (10%) and treatment discontinuation (2%), and a safety profile ROS1 TKIs Activity only t TKI-naive t chemotherapy chemotherapy consistent with its ROS1-selective, TRK sparing design IC-ORR (BICR) 48% 85% 83% Encouraging preliminary data in a TKI-naive population No CNS 71% 91% support ongoing investigation in the front-line setting IC-DOR progression : 12 months : 12 months among confirmed CNS responders Tab out off March 21,2025 9 wclc.iaslc.org

[Slide 1] ASC 2023 Conference #WCLC25 Cancer ARROS-1: G2032R Resistance Mutation and CNS Subgroups ROS1 G2032R Resistance Mutation Measurable CNS lesions by BICR at baseline Advanced ROS1+ 1 prior ROS1 TKI Advanced ROS1+ NSCLC Any prior ROS1 TKI (crizotinib or entrectinib) NSCLC Any prior ROS1 TKI Prior crizotinib only 1 chemotherapy 1 chemotherapy 1 chemotherapy 1 chemotherapy Analysis by BICR Analysis by BICR ORR, % (n/N) 54% (14/26) 83% (5/6) IC-ORR, % (n/N) 48% (27/56) 85% (11/13) (95% ci] [33,73] 36, 100] 195% ci] (35, 62] (55, 98] IC-CR % (n/N) 20% (11/56) 54% (7/13) % DOR t 6 months 79% 80% (95% CI] [47,93] [20, 97] % IC-DOR : 6 months 79% 91% 95% ci] [56, 91] [51,99] % DOR t 12 months 60% 80% % IC-DOR : 12 months 71% 91% 95% ci] [28,81] [20,97] (95% ci] [46, 87] [51,99] Responses were also observed in patients with CNS responses also observed in patients who had received 21 prior brain- ROS1 G2032R mutation following >2 prior ROS1 TKIs : chemotherapy, penetrant TKI. including prior entrectinib, forfatinib, repotrectinib. or including forlatinib or repotrectinib taletrectinib IC-ORR: 37% (16/43 95% CI 23, 53]), including 4 IC-CRs Other ROS1 resistance mutations, including G1957A L1982V, S1986F, No CNS progression was observed among patients who entered the study F2004C/V, G2032K, and D2033N without brain metastases at baseline per BICR Patients received zidesamtinib as their first TKI designed with activity against ROS1 02032R includes 2 unconfirmed intracranial partial responses (PR). Analyses of DOR based on Kaplan-Meier estimates. Analyses of DOR based on Kaplan-Meier estimates. One progression event among responders One CNS progression event among CNS responders (n=11). (ats off March 21, 2025 C. --- [Slide 2] EASLC 2025 World Conference #WCLC25 Lung Cancer ...... ARROS-1: Safety in Advanced ROS1+ NSCLC All Treatment-Emergent Adverse Events (TEAEs) in >15% of Patients Treated with Zidesamtinib 100 mg QD (N = 432) a Dose reduction due to TEAEs: 10% (43/432) Preferred or grouped term Any Grade Grade 2 3 Most common (>2 patients): peripheral edema Peripheral edema 36% 0.7% (n=8), blood CPK increased (n=4), peripheral Constipation 17% 0% sensory neuropathy (n=4), arthralgia (n=3), paresthesia (n=3) Blood CPK increased 16% 3.5% Fatigue 6 16% 0.7% Discontinuation due to TEAE: 2% (10/432) Dyspnea 15% 3.0% Most common (>2 patients): pneumonia (n=3) Patients received at least 1 dose of zidesamtinib at 100 mg QD with median duration of exposure of 5 months (range: 0. 32). The only treatment-related adverse event in >15% b Includes terms peripheral edema, peripheral swelling. edema, generalized edema. of patients was peripheral edema b (29%) includes terms fatigue, asthenia, malaise if Includes terms dyspnea, dyspnea exertional, orthopnea I ata pooled for patients a the Phase I or Phase 2 portion of ARROS I - a data cut-off of March 21,2025 CPK, creatine phosphokinase 8 wclc.iaslc.org

[Slide 1] ASLC 2025 World Conference #WCLC25 on Long Cancer SEPTEMBER ...... ARROS-1: G2032R Resistance Mutation and CNS Subgroups ROS1 G2032R Resistance Mutation Measurable CNS lesions by BICR at baseline Advanced ROS1+ 1 prior ROS1 TKI Advanced ROS1+ NSCLC Any prior ROS1 TKI (crizotinib or entrectinib) NSCLC Any prior ROS1 TKI Prior crizotinib only t chemotherapy * chemotherapy 1 chemotherapy t chemotherapy Analysis by BICR Analysis by BICR ORR, % (n/N) 54% (14/26) 83% (5/6) IC-ORR, % (n/N) 48% (27/56) 85% (11/13) 95% CI] [33, 73] [36, 100] [95% ci] [35,62] [55,98] IC-CR. % (n/N) 20% (11/56) 54% (7/13) % DOR : 6 months 79% 80% 95% ci] [47,93] [20, 97] % IC-DOR : 6 months 79% 91% 95% CI] b [56, 91] [51,99] % DOR : 12 months 60% 80% % IC-DOR : 12 months 71% 91% 95% ci] b [28, 81] [20, 97] 95% CI] [46,87] [51,99] Responses were also observed in patients with: CNS responses also observed in patients who had received 21 prior brain- ROS1 G2032R mutation following >2 prior ROS1 TKIs * chemotherapy, penetrant TKI, including prior entrectinib, lorlatinib, repotrectinib, or including lorlatinib or repotrectinib taletrectinib: IC-ORR: 37% (16/43 : 95% CI 23, 53]), including 4 IC-CRs Other ROS1 resistance mutations, including G1957A, L1982V, S1986F, No CNS progression was observed among patients who entered the study F2004C/V, G2032K, and D2033N without brain metastases at baseline per BICR Patients received zidesamtinib as their first TKI designed with activity against ROS1 G2032R. Includes 2 unconfirmed intracranial partial responses (PR). a Analyses of DOR based on Kaplan-Meier estimates Analyses of DOR based on Kaplan-Meier estimates. One progression event among responders. One CNS progression event among CNS responders (n=11). I ata cut off March 2025 IC intracrapial 6 wclc.iaslc.org --- [Slide 2] ASIC 2025 World Conference #WCLC25 Lung Cancer SEPTEMBER ...... ARROS-1: Duration of Response and Progression-Free Survival Duration of Response Progression-Free Survival Advanced ROS1+ NSCLC Any prior ROS1 TKIs 1 prior ROS1 TKI Any prior ROS1 TKIs 1 prior ROS1 TKI (range 1-4) (crizotinib or entrectinib) (range 1-4) (crizotinib or entrectinib) Kaplan-Meier Estimate * chemotherapy : chemotherapy : chemotherapy 1 chemotherapy %2 6 months 95% ci] 84% [71, 92] 93% 74. 98] 57% [47, 66] 70% [56, 81] % : 12 months [95% ci] 78% 62, 88] 93% 74, 98] 48% [38, 57] 68% [53, 79] % 2 18 months [95% CI] 62% [28, 84] 93% 74, 98] 40% [24, 55] 68% [53, 79] Tata out off March 21, 2025 100 93% 93% 93% 100 "Any prior ROST TKL Emerging median DOR of 22 months (95% CE 17.NET continues to manure 75 84% 75 70% 68% 68% Median PFS was 9.7 5.5. NE] months with median follow up of Paters Response 2 $ 78% 50 62% Progression-Free Surval 50 11.1 months trange 02-25-6) 57% 48% 1 prior ROS1 110 (crizotinib)(C) or 40% 25 25 entrectinib] Emerging median DOR of 22 months 95% DI 22. NE] and median PFS of 23.8 0 0 months 295% Ct 23.8 NE) 0 0 12 18 24 Months 0 0 12 18 24 Months continue to mature median ALRISK ALROA folow up was 11.8 months Any proor ROST Tide 11 40 10 3 - ROST DOB 117 04 27 $ trange 1.2-25.6) Prior Cer only 29 26 0 3 0 Prior or only 55 37 14 4 0 In patients that received prior crizotinib only, there were no progression events among responders (DOR range: 7.3+ to 23.2+ months). PFS rate was 89% (95% Cl: 70, 96) at 6, 12, and 18 months with median not reached. In patients that received >2 prior ROS1 TKIs 1 chemotherapy, DOR rate was 71% (95% Cl: 46, 86) at 6 months and 56% (95% CI: 29, 76) at 12 months. 5 wclc.iaslc.org --- [Slide 3] ASC World Conference #WCLC25 Lung Cancer ARROS-1 Preliminary Data: TKI-Naive Patients with Advanced ROS1+ NSCLC TKI-naive advanced Response-evaluable TKI-naive advanced Measurable intracranial lesions ROS1+ NSCLC ROS1+ NSCLC n 35 n= 6 Analysis by BICR Analysis by BICR ORR, % (n/N) 89% (31/35) IC-ORR, % (n/N) 83% (5/6) CR, % (n/N) 9% (3/35) % DOR : 6 months [95% CI] 96% [76, 99] IC-CR, % (n/N) 67% (4/6) % DOR 2 12 months [95% CI] 96% [76, 99] IC-DOR No CNS progression events among DOR range 1.9+ to 13.9+ months intracranial responders 1 Includes 1 unconfirmed CR following confirmed partial response (PR). IC-DOR range 4.6+ to 11.1+ months . Analyses of DOR based on Kaplan-Meier estimates 40 ROS1 TKI-naive Best %change in target lesions 20 0 No prior 2 chemotherapy $ 1 prior line of 00 chemotherapy 8 100 so PD so PR PR PM PR PM PR PR PM PR PR PR PR PR PM CR PR PR PM PM PR PR PM PR PR UCR PR PR PR PR PM CR Date for patients treated with ridesar with 100Γ or by August 31, 2024 in the Phose 2) portion of ARROS I with a data cut off of March 21, 2025 Patients may have received up to 1 prior line of chemoltherapy 7 wclc.iaslc.org